ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Nevertheless, since the development of a tyrosine kinase inhibitor targeting BCR-ABL1 in the 90s century, CML can be effectively treated using the 2-phenyl-aminopyrimidine imatinib resulting in more than 80% 10-years survival rates in a life-long treatment regimen (Druker et al., 1996; Hochhaus et al., 2017).